👇
抗癌研究从未停下脚步!欢迎大家点击转发,把好消息分享给更多朋友哦!
内容制作
封面图片:摄图网+稿定设计
责任编辑:觅健科普君
参考文献:
[1] Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing JB, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019 Jan 8;116((2)):609–18.
[2] Kudo M. Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer. 2022 Feb 18;11(2):87-93.
[3] Rivera Vargas T, Apetoh L. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors? Front Immunol. 2019, 10:1181.
[4] Li H., Qin S., Liu Y., Chen Z., Ren Z., Xiong J., Meng Z., Zhang X., Wang L., Zhang X., et al. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Des. Dev. Ther. 2021;15:1873–1882.
[5] Choi C., Yoo G.S., Cho W.K., Park H.C. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J. Gastroenterol. 2019;25:2416–2429.
[6] Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol. 2022 Jun 10;13:896752.